Factory 99% Letermovir CAS 917389-32-3 Chemical Intermediate Letermovir

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A377
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Letermovir
• CAS: 917389-32-3
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 100g
• Function: Antiviral
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product Name	Letermovir
Appearance	White Powder
CAS NO.	917389-32-3
Molecular Formula	C29H28F4N4O4
Storage	Keep in a cool, dry, dark location

 

Letermovir is an antiviral medication belonging to the class of CMV (Cytomegalovirus) inhibitors. It specifically targets the viral terminase complex, which is essential for the replication of CMV, and thereby inhibits its activity.

 

 

1. Prevention of CMV Infection: Administered to patients with a weakened immune system, such as those undergoing organ transplantation or those with HIV/AIDS, to prevent the occurrence or recurrence of CMV infection.
2. Treatment of CMV Disease: In some cases, Letermovir may also be used to treat active CMV disease, especially when other antiviral therapies have failed or are not tolerated.
3. Combination Therapy: Often used in combination with other antiviral drugs to enhance the therapeutic effect and reduce the risk of resistance development.

1. Inhibition of CMV Replication: By targeting the viral terminase complex, Letermovir effectively inhibits the replication of CMV, thereby reducing the viral load in the body.
2. Prevention of CMV-Related Complications: By suppressing CMV replication, Letermovir helps to prevent CMV-related complications, such as pneumonia, retinitis, and gastrointestinal disease, which can be life-threatening in immunocompromised patients.
3. Improvement of Clinical Outcomes: Use of Letermovir has been associated with improved clinical outcomes, including reduced mortality and morbidity, in patients with CMV infection or disease.